The missing link in the recognition of corneal abnormalities
May 17, 2022
Polarisation-sensitive optical coherence tomography has facilitated early diagnosis of disease before it becomes apparent on topography.
© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
All Articles
Strategic alliance combines resources to develop treatment option for dry eye syndrome
May 18, 2022
BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).
Making strides in ophthalmology with modern gene therapy techniques
May 16, 2022
Promising gene therapies in development are pinpointing steps in the pathogenic cascades involved in ocular diseases, such as VEGF for wet AMD and CFI for dry AMD.
Weekly review in ophthalmology: 7 May - 13 May
May 13, 2022
An end-of-week review of what happened in ophthalmology from 7 May to 13 May.
Promising early data with intravitreal diabetic macular ischaemia candidate
May 12, 2022
An ischaemia modulator has demonstrated it is safe and well tolerated in a Phase 1/2a trial in diabetic macular ischaemia patients.
Acute and chronic care required for eye with SJS/TEN ocular involvement
May 11, 2022
Patients are at risk for developing severe dry eye and ocular surface disease.
A new treatment paradigm with ab-interno canaloplasty for POAG
May 10, 2022
With minimally invasive surgery procedures becoming increasingly popular in glaucoma management, canaloplasty using an ab-interno surgical technique offers enhanced natural aqueous outflow in open-angle glaucoma.
Half a century of developments in ophthalmology: One doctor’s reflections
May 09, 2022
Dr Goes reflects on a life at the forefront of ophthalmology, considering advancements in technology and the knowledge that has changed his practice and improved outcomes for patients.
Positive topline data from Saturn-2 Phase 3 trial encourages Tarsus to file NDA in 2022
May 08, 2022
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
Nanoemulsion formulation enhances IOP reduction, study finds
May 07, 2022
In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.